SCHEMBL19975358

SCHEMBL19975358

COc1ccccc1NC(=O)C(=O)C(C)N(C=O)c1ccccc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
CASP6 P55212 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 2/20 0.44
LPAR1 Q92633 1/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
EGFR P00533 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975357 1.00 POLB (0.45) POLBCASP6TDP1ALDH1A1KMT2A
SCHEMBL21183522 0.88 L3MBTL1 (0.46) ALDH1A1KMT2AKDM4EL3MBTL1NPC1
SCHEMBL19975449 0.85 L3MBTL1 (0.36) ALDH1A1KMT2AL3MBTL1LMNAMEN1
SCHEMBL19974888 0.85 L3MBTL1 (0.36) ALDH1A1KMT2AL3MBTL1LMNAMEN1
SCHEMBL19974891 0.85 L3MBTL1 (0.36) ALDH1A1KMT2AL3MBTL1LMNAMEN1
SCHEMBL21176236 0.84 MAPK1 (0.40) POLBALDH1A1KMT2ARAB9ALMNA
SCHEMBL21183534 0.84 MAPK1 (0.40) POLBALDH1A1KMT2ARAB9ALMNA
SCHEMBL19975472 0.84 MAPK1 (0.40) POLBALDH1A1KMT2ARAB9ALMNA
SCHEMBL21176210 0.83 HPGD (0.43) POLBALDH1A1KMT2AKDM4EL3MBTL1
SCHEMBL19975096 0.82 HPGD (0.47) ALDH1A1KMT2AMAPTMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885CASP6 295/4885TDP1 1016/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C POLB 617/4885CASP6 212/4885TDP1 911/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885CASP6 295/4885TDP1 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.